Hand exercises may shield nerves from chemo side effects
NCT ID NCT05374876
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study tests whether a special hand therapy program can prevent chemotherapy-induced nerve damage in the hands of people with pancreatic cancer. Participants are randomly assigned to either the hand therapy or traditional occupational therapy. The goal is to see if the hand therapy is practical and worth testing in a larger trial.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Hand therapy
- What this could lead to
- If effective, this hand therapy could help prevent painful nerve damage from chemotherapy, improving quality of life during treatment.
- What could go wrong
- This is a small pilot study testing feasibility, not effectiveness. The therapy may not prevent nerve damage, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
49 people
The number who actually took part.
- Started
-
May 2016
- Finished
-
Sep 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients with adenocarcinoma of the pancreas who will receive chemotherapy with albumin bound paclitaxel plus gemcitabine containing combination 2. Patients who have no prior evidence of peripheral neuropathy of the hands 3. Age 18 years or older 4. Able to sit for minimum of 30 minutes for hand therapy sessions Exclusion Criteria: 1. Patients who have received at least one dose of chemotherapy with albumin bound paclitaxel plus gemcitabine during the past 6 months 2. Patients taking duloxetine or gabapentin 3. History of peripheral neuropathy of the hands due to chemotherapy, diabetes, or other causes 4. Inability to sit for minimum of 30 minutes 5. Documented cognitive problems limiting ability to participate in hand therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adenocarcinoma of pancreas are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.